NCT01567852

Brief Summary

When undergoing ECT treatments, patient recovery time and re-orientation time may be shorter using ketamine for induction than using methohexital.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Aug 2011

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2011

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

March 28, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 30, 2012

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2013

Completed
1.8 years until next milestone

Results Posted

Study results publicly available

December 30, 2014

Completed
Last Updated

December 30, 2014

Status Verified

June 1, 2014

Enrollment Period

1.6 years

First QC Date

March 28, 2012

Results QC Date

May 21, 2014

Last Update Submit

December 15, 2014

Conditions

Keywords

orientationpost-anesthesia recoveryelectroconvulsive therapy

Outcome Measures

Primary Outcomes (2)

  • Re-orientation Time

    Patients will be scored based on 5 questions (name, age, year, day of week, location). Each patient will be scored prior to induction as to how many questions they score correctly. Patient is deemed re-oriented when they score the same as baseline after the treatment.

    1 hour

  • Recovery Time

    Recovery was assessed using 5 criteria (blood pressure, voluntary movement, oxygen requirement, consciousness, respiratory effort). Each criteria was scored from 0-2, with a full score of 10. The patient is scored at baseline, and is deemed recovered when all criteria has reached baseline score again.

    1 hour

Study Arms (2)

Ketamine First

EXPERIMENTAL

This arm will receive ketamine for induction first, followed by alternating treatments between methohexital and ketamine

Drug: KetamineDrug: Methohexital

Methohexital First

EXPERIMENTAL

This arm will receive Methohexital first for induction, followed by alternating treatments between ketamine and methohexital.

Drug: KetamineDrug: Methohexital

Interventions

Ketamine (1.5mg/kg) will be given for induction, with room to titrate up to induction effect

Ketamine FirstMethohexital First

Methohexital (1.5mg/kg) will be given for induction

Ketamine FirstMethohexital First

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • All patients eligible for ECT with a primary mood disorder (bipolar disorder, major depressive disorder) will be eligible to participate in this study. - Patients must have decisional capacity and must be able to consent for this study.

You may not qualify if:

  • patients with a primary psychotic disorder (schizophrenia, schizoaffective disorder); patients designated as having an American Society of Anesthesiologist (ASA) Status of greater than 3;
  • patients with a known allergic reactions to methohexital , ketamine and succinylcholine;
  • patients with current or previous history of aneurysms, intracranial bleeds, or intracranial hypertension;
  • patients with uncontrolled severe hypertension.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of New Mexico

Albuquerque, New Mexico, 87131, United States

Location

MeSH Terms

Conditions

Orientation, Spatial

Interventions

KetamineMethohexital

Condition Hierarchy (Ancestors)

Spatial BehaviorBehavior

Intervention Hierarchy (Ancestors)

CyclohexanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsBarbituratesPyrimidinonesPyrimidinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Results Point of Contact

Title
Dr. Tony Yen
Organization
University of NewMexico

Study Officials

  • Tony Yen, MD

    University of New Mexico

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 28, 2012

First Posted

March 30, 2012

Study Start

August 1, 2011

Primary Completion

March 1, 2013

Study Completion

March 1, 2013

Last Updated

December 30, 2014

Results First Posted

December 30, 2014

Record last verified: 2014-06

Locations